《异动股》中国同辐(01763.HK)续涨18%创上市新高 成交增
中国同辐(01763.HK)突破今年1月所创上市高位24.6元,最高见26.3元,现造25.95元,续扬18%,一向薄弱成交倍增至235万股,涉资5,553万元。
同辐为内地大型显像诊断与治疗用放射性药品,尿素呼气试验药盒和测试仪及放射免疫分析药盒制造商。股份於2018年7月以每股21.6元来港上市,净筹约16.1亿元。
该公司上周四公布,与内地生态环境部核与辐射安全中心签订辐射安全与环境保护合作框架协议,双方将共同合作申报在辐射安全、环境保护等方面的合作项目,争取国家及地方各类财政经费支持,支撑开展核技术利用辐射安全相关研究。同时,双方可於核技术利用辐射安全及相关领域开展技术支持与合作,合作范围包括但不限於核技术利用辐射安全关键技术研究、放射源安全管理和应用、放射性物品运输、辐射环境监测、专业培训、技术谘询与服务、核技术利用辐射安全科普等领域等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.